Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto
Hunt III, Stephen Warren,Phillips, Martin Douglas,Matunas, Robert,Chen, Herman,Betancourt, Aimesther,Uzarama, Charles,Thibert, Roch
申请号：
AU2020202784
公开号：
AU2020202784A1
申请日:
2020.04.27
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020202784A120200514.pdf#####:1 Interwovn NRPortbl DCCSXD 20129404_l.docx-27/04/2020 ABSTRACT A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to "ATR101") suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome. - 53-
